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TO THE EDITOR
Wound healing is a complex process
involving cell–cell and cell–matrix inter-
actions modulated by the surrounding
microenvironment. One of the key
events in this process is re-epithelializa-
tion: the directed migration and prolif-
eration of epithelial cells to resurface the
wound. Numerous studies have docu-
mented that the migration of cells into
the wound site is regulated by autocrine
and paracrine signaling of growth fac-
tors (Gurtner et al., 2008). Epidermal
growth factor (EGF) is an extensively
investigated growth factor, which is
implicated in keratinocyte adhesion
and migration, as well as fibroblast func-
tion, and granulation tissue formation
(Hardwicke et al., 2008). Conflicting
reports exist regarding the ability of
EGF alone to modulate wound healing
(Brown et al., 1989; Cohen et al., 1995).
A systematic review concluded that EGF
is effective as an adjuvant but not as
monotherapy for diabetic foot ulcers
(Buchberger et al., 2011). The reason
for this lack of efficacy of EGF in healing
wounds may be derived from the
mechanism of delivery, in that it needs
to be intimately associated with the
extracellular matrix to limit proteolysis
(Macri and Clark, 2009).
Various approaches for delivering
EGF to the wound have been attempted
with the goal of maximizing therapeutic
effects with minimal dose (to minimize
potential adverse effects). EGF conju-
gated to copolymers composed of
poly(e-caprolactone) (PCL) and poly
(ethyleneglycol) (PEG) improved healing
in diabetic mouse wounds, compared
with treatment with the copolymers
alone or no treatment (Choi et al.,
2008). Recent advances in materials
science have led to the development
of engineered systems such as poly-
meric microparticles for controlled
release of cytoactive factors (CFs; Lee
et al., 2011). Another method that has
received limited attention is the
covalent immobilization of CFs within
polyelectrolyte multilayer (PEM) films.
PEM films, which are formed by the
layer-by-layer deposition of polyelectro-
lytes, provide numerous advantages for
biomedical applications, such as ease of
preparation, biocompatibility, tunable
mechanical properties, spatio-temporal
control over film organization, and most
importantly, the sustained and contro-
lled contact of embedded factors with
tissue (Guthrie et al., 2013). In parti-
cular, we speculate that the nanoscopic
thickness of PEMs enables their intimate
contact with the tissue surface upon
application. When CFs are conjugated
to the PEMs, it also limits, if not
eliminates, the systemic release of
embedded CFs and the associated
potential for systemic toxicity (Agarwal
et al., 2010). Another key advantage
of the PEM films is that they can also
be easily immobilized to complex
geometries such as wound bed (Jain
et al., 2013). However, the efficacy, bio-
availability, and bioactivity of CFs such
as growth factors, when conjugated to
PEMs, have not been reported.
To address the question of the bio-
availability of growth factors within
PEMs, we fabricated PEM films with
EGF that was covalently immobilized
at varying depths within the PEMs.
The accessibility and bioactivity of
EGF immobilized within the PEM films
was determined by measuring the
migratory and proliferative responses ofAccepted article preview online 3 January 2013; published online 23 January 2014
Abbreviations: CF, cytoactive factor; EGF, epidermal growth factor; HKGS, human keratinocyte growth
supplement; NHK, neonatal human keratinocyte; PAA, poly(acrylic acid); PAH, poly(allylamine
hydrochloride); PEM, polyelectrolyte multilayer
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spontaneously immortalized human ker-
atinocytes (HaCaT) and primary neona-
tal human keratinocytes (NHK). Our
aim was to delineate the optimal design
and assembly parameters for the fabri-
cation of covalently immobilized CFs
within PEMs for future therapeutic appli-
cation in chronic wounds.
PEM films (10.5 bilayers) were fabri-
cated (Figure 1a) as previously described
(Agarwal et al., 2010) by alternating
deposition of poly(allylamine hydro-
chloride) (PAH, pH¼ 7.5) and poly
(acrylic acid) (PAA, pH¼ 7.5). EGF was
covalently modified with Sulfo-
SANPAH, a hetero-bifunctional cross-
linker and conjugated to the PEM film
using 365 nm UV light (Figure 1a). Fol-
lowing conjugation of the EGF,
additional bilayers of PAH and PAA (0,
2.5, 4.5, 6.5, 8.5, or 10.5) were depos-
ited onto the PEM (Figure 1a and b).
Immunohistochemistry confirmed the
successful immobilization of EGF within
the PEM films (Figure 1c). The ability of
HaCaT cells to attach to the various PEMs
and form focal adhesions was confirmed
by immunostaining for vinculin and actin
(Figure 1d). Cellular morphology was
observed to be similar on various surface
treatment groups, as was the appearance
and focal adhesion complex distribution
(arrows in Figure 1d).
Although EGF is a recognized
mitogen for keratinocytes, covalent
modification and immobilization onto
a surface may alter its bioactivity
(Stefonek and Masters, 2007). We
observed that EGF immobilized on
PEMs increased HaCaT proliferation as
robustly as free EGF added to the culture
medium of cells plated on either PEM or
tissue culture plastic (TCP; Figure 2a),
confirming that EGF retained its bioac-
tivity post modification and immobiliza-
tion. Even when the immobilized EGF
was overlain with an additional two
bilayers of PAH and PSS, proliferation
of primary normal human keratinocytes
(NHKs; Figure 2b) was significantly
(11.8-fold, Pp0.05) greater than those
plated on control PEMs (BSA pre-
coated). Immobilized EGF on the top
of PEMs or underneath two bilayers
also increased the cell viability by
13% when compared with cells grown
on TCP with standard keratinocyte
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Figure 1. EGF can be efficiently immobilized within PEM films. (a) Schematic depiction of the fabrication of PEMs to which EGF was conjugated. PEM films
(10.5 bilayers) were fabricated as previously described (Agarwal et al., 2010) by alternating deposition of poly(allylamine hydrochloride) (pH¼ 7.5) and
poly(acrylic acid) (pH¼ 7.5). The EGF was covalently modified with sulfo-SANPAH (SS) via EGF amine groups by adding 30 molar excess of SS to the
EGF solution and reacting overnight on a shaker. The final EGF–SS solution was dialyzed against phosphate-buffered saline to remove unreacted SS. Ten
microliters of the EGF–SS solution (diluted to 500mg ml1) was pipetted onto PEM films fabricated within the wells of a 96-well plate. Note that PEM films
were pre-coated with BSA to enhance available amine groups for EGF–SS conjugation. Once the base 10.5 bilayers of PEM were generated, a 1% (w/v) BSA
solution was pipetted into the wells, allowed to sit for 1 hour, and then rinsed in dH2O. This allowed for nonspecific adsorption of BSA on the surfaces. The
EGF-containing wells were exposed to 365 nm UV light at an intensity of 10 mW cm 2 for 5 minutes for cross-linking. Moreover, additional alternating PAH
and PAA layers (PEMs) were added if needed. (b) The summary of the treatment groups used in the study. (c) Confirmation of EGF presence within PEMs.
PEMs, with or without covalently bound EGF, were treated with anti-EGF antibody (clone PAT6E3AT, ProsPec, NJ) and Alexa Fluor 488 secondary antibody
(Invitrogen, Chicago, IL). Significant increase in fluorescence measurements (Synergy 5 plate reader, BioTek, Winooski, VT) confirmed the presence of
immobilized EGF when compared with PEMs without EGF conjugation. Interestingly, addition of PEM layers on top of the immobilized EGF did not block
access by the antibody up to 6.5 bilayers. *Po0.05 for PEMs versus other groups. (d) Immunohistochemistry demonstrates vinculin (in green, clone hVIN-1,
Abcam, Cambridge, MA) and actin (in red, Alexa Fluor 568 Phalloidin, Invitrogen) in focal adhesions of HaCaT cells plated in wells coated with PEM10.5,
PEM10.5þ EGF, PEM8þ EGFþ PEM2.5, or PEM6þ EGFþ PEM4.5. Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI, in blue, Invitrogen).
Goat Anti-Mouse Alexa Fluor 488 (Invitrogen) was used as secondary antibody. Bar¼20mm. EGF, epidermal growth factor; PAA, poly(acrylic acid); PAH,
poly(allylamine hydrochloride); PEM, polyelectrolyte multilayer.
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medium (Figure 2b). Interestingly, when
EGF was immobilized beneath four or
more PEM bilayers, NHK proliferation
was progressively reduced (Figure 2b).
This may be due to reduced availability
of EGF, and/or direct cell–polymer inter-
actions. In order to verify that observed
proliferative responses were specific to
EGF, HaCaTs were pretreated with an
anti-EGF receptor (EGFR) antibody,
before being plated on the various
PEMs. HaCaT proliferation was signifi-
cantly reduced for all the PEM treatment
groups (Figure 2c). This reduction was
comparable in all treatment groups,
supporting the conclusion of retention
of bioactivity of immobilized EGF.
EGF also increases migratory
responses of cells (Ando and Jensen,
1993). Similarly, EGF conjugated to
PEMs significantly increased the
migratory speeds of NHKs, relative to
cells cultured on PEMs without EGF
(Figure 2d). Interestingly, the number
of additional bilayers of PAH and PAA
on top of the immobilized EGF that
reduced the proliferative response
(Figure 2b) did not significantly change
the magnitude of the migratory response
(Figure 2d). Cells on unmodified PEM
layers without EGF demonstrated
decreased migration rates as compared
with cells on TCP (Figure 2d).
In summary, our results demonstrate
that covalently immobilized EGF con-
jugated either to the top of PEMs or
buried within PEMs remained bioactive
and accessible to cells, and promoted
cell proliferation and migration, the two
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Figure 2. EGF-impregnated PEMs have biological activity. (a) HaCaT cell viability on EGF-conjugated PEMs. HaCaT cells (1,250 per well) were seeded in
96-well plates previously coated with PEMs fabricated as indicated, and incubated for 5 days in medium Dulbecco’s modified Eagle medium (DMEM) and
1% serum and 1% antibiotic-antimycotic (Invitrogen, Chicago, IL). Live cell assay (Invitrogen) was utilized using calcein AM as the indicator. The dead cell
control wells were treated with 3% Saponin for 30 minutes. Viability on EGF-conjugated PEMs was not statistically different from that of cells cultured with
soluble EGF (2 ng ml1). *Po0.05 for TCP compared with all other groups. (b) NHK viability on EGF-conjugated PEMs. Five thousand cells per well were
seeded in 96 wells either on TCP, or on wells that had been previously coated with PEMs as indicated, and incubated for 3 days in EpiLife medium with
a 1% antibiotic-antimycotic (Invitrogen). One percent Human Keratinocyte Growth Supplement (HKGS, standard soluble KGM medium for NHKs including
a final concentration of 0.2 ng ml1 of EGF) was added to the groups considered as positive control. Cell viability was determined by live cell assay
(Invitrogen) using calcein AM as the indicator. The dead cell control wells were treated with 3% Saponin for 30 minutes. EGF immobilized within PEMs
significantly increased the proliferation of NHKs compared with control PEMs coated with BSA (three different cell donors, data combined), although
a trend toward a decrease in proliferation was observed with increasing the depth, starting from the cells treated with EGF buried in four PEM bilayers.
Cells that were plated onto immobilized EGF on the top of BSA-coated PEMs or EGF buried underneath 2.5 bilayers of BSA-coated PEMs proliferated significantly
more than the cells grown on TCP with standard soluble HKGS supplement (KGM medium, Po0.01 for both comparisons). In addition, cells cultured in the
aforementioned two EGF groups proliferated comparably to the cells grown in PEM10.5þ soluble KGM medium (P¼ 0.1 for both). *Po0.05 versus all other
groups. (c) Anti-EGF receptor (EGFR) antibody prevents cell response to EGF conjugated to PEM. HaCaT cells were plated on EGF-PEM–coated wells; some
cells were pretreated with anti-EGFR antibody (clone PAT6E3AT, ProsPec, NJ), and then cultivated an additional 5 days in medium (DMEM and 1% serum
and 1% antibiotic-antimycotic (Invitrogen). Cells in control wells were treated with anti-GFAP (polyclonal, Abcam, Cambridge, MA), which is not expressed
in HaCaTs. Viability assayed as in a with calcein AM. Anti-EGFR antibody prevents proliferation in response to EGF conjugated to PEMs. (d) NHK migratory
speed on EGF-PEMs. The migratory speed of NHK plated on EGF-PEMs as noted was measured by time-lapse image analysis, as described previously (Sivamani
et al., 2009). Cells from three different NHK donors were used and at least 179 cells were tracked per treatment group. *Po0.05 versus non-EGF-containing
groups. AB, antibody; EGF, epidermal growth factor; KGM, keratinocyte growth medium; NHK, normal human keratinocyte; PEM, polyelectrolyte multilayer;
TCP, tissue culture plastic.
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key parameters for wound healing.
Overlaying the immobilized EGF with
increasing numbers of bilayers of PAH
and PAA diminished the proliferative
response, but did not alter the migratory
response, suggesting that the PEM plat-
form can be tuned to target-specific cell
responses. Further experiments are
needed to investigate this difference.
The EGF conjugated to PEMs can target
cellular-reparative responses to acceler-
ate wound healing, while avoiding
many of the concerns associated with
systemic delivery and systemic diffusion
of free growth factors. PEMs represent
facile materials platform for integration
into wound therapeutic strategies, and
can incorporate other bioactives, (e.g.,
antimicrobial silver nanoparticles)
(Agarwal et al., 2010), providing the
potential for translation into a clinical
approach to improve healing in patients
with chronic wounds.
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Overexpressed b-Catenin Localizes to Plasma Membrane in
Respiratory Papillomas
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TO THE EDITOR
Recurrent respiratory papillomatosis
(RRP), a disease characterized by recur-
rent tumors of the upper airway, is
caused by human papillomavirus
(HPV) types 6 and 11 (Doorbar et al.,
2012). It has been suggested that the
HPV early protein E6 regulates the
function of the oncogene b-catenin,
including a recent report, which shows
that HPV16 E6 can induce nuclear
localization of b-catenin in a cuta-
neous mouse model (Bonilla-Delgado
et al., 2012). b-catenin’s function in the
cell is highly dependent on its
localization (Brembeck et al., 2006).Accepted article preview online 29 January 2014; published online 27 February 2014
Abbreviations: HPV, human papillomavirus; RRP, recurrent respiratory papillomatosis
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